A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Alaunos Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 0 |
| Net Income | -4.0M | -4.7M | -35M | -38M | -79M | -80M |
| EPS | $-2.30 | $-2.92 | $-21.97 | $-26.10 | $-55.50 | $-57.00 |
| Free Cash Flow | 0 | -5.0M | -30M | -29M | -65M | -67M |
| ROIC | -372.0% | -184.3% | -429.2% | -68.2% | -1000.9% | -64.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.34 | 0.31 | 0.87 | 0.42 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -4.1M | -4.8M | -34M | -35M | -78M | -80M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -143.6% | -111.8% | -557.2% | -97.9% | -135.6% | -64.5% |
| Shares Outstanding | 2M | 2M | 2M | 1M | 1M | 1M |
| Metric | 2017 | 2018 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | 0 | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -53M | -54M | -80M | -78M | -35M | -34M | -4.8M | -4.1M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -73M | 137M | -80M | -79M | -38M | -35M | -4.7M | -4.0M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 1.3M | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -40.0% | -49.8% | -64.5% | N/M | -68.2% | N/M | -184.3% | N/M |
| ROE | N/A | 160.4% | -64.5% | -135.6% | -97.9% | -557.2% | -111.8% | -143.6% |
| ROA | -69.4% | 144.4% | -54.6% | -83.0% | -58.1% | -425.3% | -84.9% | -108.1% |
| Cash Flow | ||||||||
| Op. Cash Flow | -55M | -49M | -57M | -61M | -29M | -30M | -5.0M | -2.9M |
| Free Cash Flow | -55M | -50M | -67M | -65M | -29M | -30M | -5.0M | 0 |
| Owner Earnings | -63M | -58M | -65M | -75M | -36M | -35M | -5.4M | -3.3M |
| CapEx | 737K | 459K | 9.8M | 3.3M | 216K | 197K | 0 | 0 |
| Maint. CapEx | 369K | 575K | 1.1M | 2.6M | 2.8M | 2.3M | 2K | 2K |
| Growth CapEx | 368K | 0 | 8.7M | 726K | 0 | 0 | N/A | 0 |
| D&A | 369K | 575K | 1.1M | 2.6M | 2.8M | 2.3M | 2K | 2K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 1.6M | 0 | 0 | 45K | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.7% | N/A | N/A | 0.0% | N/A | N/A | 0.0% |
| Stock-Based Comp | 8.5M | 7.5M | 6.8M | 11M | 3.5M | 2.8M | 435K | 435K |
| Debt Repayment | 0 | 0 | 0 | 0 | 8.3M | 18M | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | -115M | -52M | -5.5M | N/A | N/A | -1.9M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.9M |
| Long-Term Debt | N/A | N/A | 0 | 16M | 17M | N/A | N/A | N/A |
| Debt/Equity | -0.60 | 0.11 | 0.00 | 0.42 | 0.87 | 0.31 | 0.34 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | -65.2 | -11.1 | -17.8 | N/A | N/A |
| Equity | -97M | 86M | 124M | 58M | 39M | 6.3M | 2.1M | 2.8M |
| Total Assets | 106M | 95M | 146M | 95M | 65M | 8.3M | 2.8M | 3.7M |
| Total Liabilities | 58M | 9.5M | 22M | 37M | 26M | 2.0M | 692K | 921K |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -712M | -566M | -764M | -843M | -881M | -916M | -920M | -920M |
| Working Capital | 70M | 75M | 112M | 63M | 30M | 6.3M | 2.1M | 2.1M |
| Current Assets | 91M | 84M | 131M | 79M | 54M | 8.3M | 2.8M | 2.8M |
| Current Liabilities | 21M | 9.5M | 18M | 16M | 24M | 2.0M | 692K | 692K |
| Per Share Data | ||||||||
| EPS | -79.50 | 144.00 | -57.00 | -55.50 | -26.10 | -21.97 | -2.92 | -2.30 |
| Owner EPS | -68.90 | -60.40 | -46.31 | -52.74 | -24.57 | -22.04 | -3.37 | -1.50 |
| Book Value | -105.05 | 89.77 | 88.36 | 40.92 | 26.67 | 3.94 | 1.29 | 1.26 |
| Cash Flow/Share | -59.32 | -51.89 | -40.63 | -43.32 | -20.22 | -18.85 | -3.10 | -1.80 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 1.0M | 1.4M | 1.4M | 1.4M | 1.6M | 1.6M | 2.2M |
| Valuation | ||||||||
| P/E Ratio | N/A | 1.7 | N/A | N/A | N/A | N/A | N/A | -1.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.8 | 4.6 | 4.1 | 3.1 | 2.7 | 1.4 | 2.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -10.0% | -21.0% | -11.8% | -27.4% | -24.3% | -180.7% | -168.6% | N/A |
| Market Cap | 553M | 237M | 566M | 236M | 121M | 17M | 2.9M | 6.7M |
| Avg. Price | 879.46 | 521.65 | 453.01 | 403.52 | 166.32 | 58.21 | 9.37 | 2.99 |
| Year-End Price | 600.00 | 249.00 | 403.50 | 166.50 | 84.00 | 10.50 | 1.84 | 2.99 |
Alaunos Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Alaunos Therapeutics, Inc. (TCRT) has a 5-year average return on invested capital (ROIC) of -105.7%. This is below average and may indicate limited pricing power.
Alaunos Therapeutics, Inc. (TCRT) has a market capitalization of $7M. It is classified as a small-cap stock.
Alaunos Therapeutics, Inc. (TCRT) does not currently pay a regular dividend.
Alaunos Therapeutics, Inc. (TCRT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Alaunos Therapeutics, Inc. (TCRT) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Alaunos Therapeutics, Inc. (TCRT) has a debt-to-equity ratio of 0.34. This indicates a conservatively financed balance sheet.
Alaunos Therapeutics, Inc. (TCRT) reported earnings per share (EPS) of $-2.92 in its most recent fiscal year.
Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -111.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Alaunos Therapeutics, Inc. (TCRT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Alaunos Therapeutics, Inc. (TCRT) has a book value per share of $1.29, based on its most recent annual SEC filing.
No recent press releases.